Brind.
  1. Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
  2. GSK's failed trials opened a market niche for Trevi Therapeutics.

Trevi Therapeutics, Inc. is seeking regulatory approval from the FDA for Haduvio, an extended-release formulation of nalbuphine.

2 reports, 2 independent Updated Aug 1
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Trevi Therapeutics, Inc. is seeking regulatory approval from the FDA for Haduvio, an extended-release formulation of nalbuphine.

Who's involved

What this event is mainly about
Food and Drug Administration

How it developed

Newest first. Tap a step to see who reported it.
  1. Trevi Therapeutics is engaging with the FDA regarding the development path for nalbuphine ER.1 source
  2. Company seeks FDA approval for Haduvio market access.1 source

Keep exploring

Part of

GSK's failed trials opened a market niche for Trevi Therapeutics. All 1 developments

Within Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.

The entities involved

Coverage

Newest first; wire copies grouped